JPM
JPMorgan Chase & Co.
JPM has slightly lower modeled downside risk, despite its lower overall score.
MET
MetLife, Inc.
MET has the edge over JPM overall, supported by stronger valuation.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
MET Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
MET's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MET.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM has the edge over MET in the historical PE scenario, which offers more potential upside but is not a forecast.
MET PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8x | $61.38 | -40% |
| Forward | 9.4x | $102 | — |
| Current | 13x | $102 | — |
| Fair | 15x | $115 | +13% |
| Expensive | 25x | $191 | +88% |
Historical ranges are pointers, not guarantees.
MET's PE is in its fair range at 13x. If earnings grow as analysts expect, today's price would be 9.4x next year's earnings, in its cheap range.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
MET Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect MET's earnings to grow and its profitability to improve, with its revenue holding steady.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
MET Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.87 | +42% |
| Q3 2026 | $7.68 | +45% |
| Q2 2026 | $5.23 | -11% |
| Q1 2026 | $5.17 | -16% |
| Q4 2025 | $4.71 | -21% |
| Q3 2025 | $5.28 | +6.5% |
| Q2 2025 | $5.87 | +58% |
| Q1 2025 | $6.12 | +110% |
| Q4 2024 | $5.94 | +225% |
MET earned $7.68 per share over the past year, up 45% from the year before.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM has the edge over MET on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over MET on profitability, with a higher operating margin.
MET Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.5B | +18% |
| Q2 2026 | $19.2B | +10% |
| Q1 2026 | $19.1B | +2.7% |
| Q4 2025 | $23.8B | +28% |
| Q3 2025 | $17.4B | -5.9% |
| Q2 2025 | $17.3B | -2.7% |
| Q1 2025 | $18.6B | +16% |
| Q4 2024 | $18.7B | -1.9% |
MET's revenue has grown year over year for four quarters in a row: $20.5B last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.9% | -0.6 points |
| Q2 2026 | 8.4% | +0.3 points |
| Q1 2026 | 8.6% | +0.9 points |
| Q4 2025 | 7% | -0.4 points |
| Q3 2025 | 9.5% | -1.3 points |
| Q2 2025 | 8% | +1.3 points |
| Q1 2025 | 7.6% | +1.1 points |
| Q4 2024 | 7.4% | +2.5 points |
MET's operating margin was 8.9% last quarter, down 0.6 points from the same quarter a year ago.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
MET Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2B | -44% |
| Q2 2026 | $2.2B | +1.9% |
| Q1 2026 | $2.7B | -37% |
| Q4 2025 | $7.1B | +53% |
| Q3 2025 | $3.6B | -14% |
| Q2 2025 | $2.2B | -37% |
| Q1 2025 | $4.3B | +83% |
| Q4 2024 | $4.6B | -11% |
MET has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has 2.7B diluted shares, down 3.1% from a year ago, with $24.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
MET Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.1% | -7M shares |
| 1 year | -4.4% | -29.2M shares |
| 3 years | -15% | -116M shares |
| 5 years | -26% | -221M shares |
| Available history | -32% | -305M shares |
MET has the edge over JPM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $651M |
| Q2 2026 | $722M |
| Q1 2026 | $755M |
| Q4 2025 | $460M |
| Q3 2025 | $502M |
| Q2 2025 | $510M |
| Q1 2025 | $1.4B |
| Q4 2024 | $406M |
MET spent $2.6B buying back its own shares over the past year, down 8.5% from the year before.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
MET Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.1x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -2.6x | Net Cash |
| Q4 2025 | -2.8x | Net Cash |
| Q3 2025 | -2.6x | Net Cash |
| Q2 2025 | -2.7x | Net Cash |
| Q1 2025 | -2.7x | Net Cash |
| Q4 2024 | -3.3x | Net Cash |
MET has the edge over JPM on leverage, with a lower net debt burden relative to earnings.
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
MET Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.6 | Neutral |
| Stochastic | 58.9 | Neutral |
MET's weekly RSI is 66 (neutral) and its Stochastic is 59 (neutral).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
MET PE vs Financial Services Sector
| Metric | MET | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 1.8% above |
| PE % | 41 | 63 | 22 pts below |
MET has the edge over JPM on valuation relative to its sector.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
MET Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $98.8 | 3.1% above |
| 20 week MA | $96.8 | 5.3% above |
| 50 week MA | $85.6 | 19% above |
| 100 week MA | $82.5 | 23% above |
| 200 week MA | $75.3 | 35% above |
MET has the edge over JPM on trend strength, trading above more of its moving averages.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.
MET Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.8 | $46.3 | -8.9% |
| 2021 | $46.3 | $61.8 | +33% |
| 2022 | $61.8 | $72.3 | +17% |
| 2023 | $72.3 | $66.1 | -8.5% |
| 2024 | $66.1 | $82.3 | +24% |
| 2025 | $82.3 | $80.3 | -2.4% |
| 2026 YTD | $80.3 | $101.9 | +27% |
MET has the edge over JPM on returns for 2026, with the stronger performance.